Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02580669
Other study ID # 9090
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date June 16, 2014
Est. completion date February 13, 2017

Study information

Verified date May 2021
Source University Hospital, Montpellier
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to show pattern differences of vasoreactivity and connectivity between Progressive Multiple Sclerosis and Relapsing Remitting Multiple Sclerosis, by the use of methods of advanced brain MRIs and the Diffusion Tensor Imaging , and correlate these differences with Clinical disability and cognitive disorder results.


Description:

The goal of this study is to show pattern differences of vasoreactivity and connectivity between Progressive Multiple Sclerosis and Relapsing Remitting Multiple Sclerosis, by the use of methods of advanced brain MRIs, and correlate these differences with Clinical disability and cognitive disorder results. The modification of the Diffusion Tensor Imaging are well known in these two groups, as well as their link with the occurrence of movement and cognitive disorder. The study of the vasoreactivity during MRI aims to confront our results to the available data sources.


Recruitment information / eligibility

Status Terminated
Enrollment 70
Est. completion date February 13, 2017
Est. primary completion date February 13, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 50 Years
Eligibility Inclusion Criteria : - For Both patients and healthy volunteers : - Age limits = 30 et = 50 years - Subject able to understand the nature, the aim and the methodology of the study. - Collection of the informed consent - Affiliation or recipient with the mode of social security. - For the patients : - Suffering from progressive multiple sclerosis (primary progressive forms or secondary progressive forms) OR - Suffering from relapsing-remitting multiple sclerosis Exclusion Criteria : - For Both patients and healthy volunteers : - Systemic pathology with neurological manifestations - Antecedent of psychiatric disorders including psychosis (Except anxious depressive disorder) - Subject presenting contraindications in MRI (Ferromagnetic foreign bodies, pace-maker) - Claustrophobia - Women pregnant or Breast-feeding - Person with majority age protected by the law (supervision, trusteeship or under safeguard of justice). - Subject unable to understand the nature and the aim of the study and/or communication difficulties with investigator - Antecedent of serious cranial trauma (according to classification) of ischaemic stroke ou intracranial hematoma. - For the patients : - Antecedent of serious cranial trauma (according to classification), anterior or evolutive neurologic disease other than multiple sclerosis - Recent relapse of multiple sclerosis - For the healthy volunteers : - Antecedent of serious cranial trauma (according to classification), anterior or evolutive neurologic disease - Antecedent of neurological disease - In period of exclusion relative to another protocol or which the annual amount of the allowances maximum of 4500 € was reached.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Neuropsychological assessment
A neuropsychological assessment is done
Neurologic consultation
A neurologic consultation is done
MRIs (with vasoreactivity testing)
MRIs (with vasoreactivity testing) is done

Locations

Country Name City State
France Hopital Gui de Chauliac -Service de Neurologie Montpellier

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Montpellier Genzyme, a Sanofi Company

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cerebral vasoreactivity measured by diffusion imaging MRI (quantitative variable) :parameter which allow us to estimate the organization of the white matter tracts 2 months
Secondary Comparison of fonctional connective cards at Resting state somatomotor network and default mode network 2 months
Secondary Cognitive disorders Neuropsychological test results (quantitative and quantitative variable) 2 months
See also
  Status Clinical Trial Phase
Completed NCT02861014 - A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) Phase 3
Terminated NCT01435993 - Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis Phase 1
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Completed NCT02410200 - Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS Phase 2
Completed NCT03975413 - Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis
Completed NCT05080270 - Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis Early Phase 1
Completed NCT01116427 - A Cooperative Clinical Study of Abatacept in Multiple Sclerosis Phase 2
Completed NCT01108887 - An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmartâ„¢. N/A
Completed NCT01141751 - An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy N/A
Completed NCT00097331 - Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis Phase 2
Completed NCT01909492 - Measurement of Relaxin Peptide in Multiple Sclerosis (MS)
Completed NCT04121221 - A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS Phase 3
Not yet recruiting NCT05290688 - Cellular microRNA Signatures in Multiple Sclerosis N/A
Withdrawn NCT04880577 - Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis Phase 2
Completed NCT04528121 - Effect of CoDuSe Balance Training and Step Square Exercises on Risk of Fall in Multiple Sclerosis N/A
Recruiting NCT04002934 - Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis Phase 2
Recruiting NCT05019248 - Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
Completed NCT04580381 - Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
Completed NCT00071838 - Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis Phase 2